MX2017006744A - Composiciones adyuvantes y metodos relacionados. - Google Patents

Composiciones adyuvantes y metodos relacionados.

Info

Publication number
MX2017006744A
MX2017006744A MX2017006744A MX2017006744A MX2017006744A MX 2017006744 A MX2017006744 A MX 2017006744A MX 2017006744 A MX2017006744 A MX 2017006744A MX 2017006744 A MX2017006744 A MX 2017006744A MX 2017006744 A MX2017006744 A MX 2017006744A
Authority
MX
Mexico
Prior art keywords
present disclosure
related methods
composition
adjuvant compositions
adjuvant composition
Prior art date
Application number
MX2017006744A
Other languages
English (en)
Inventor
J Miller Timothy
Ann Pfannenstiel Mary
Original Assignee
Vaxliant Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxliant Llc filed Critical Vaxliant Llc
Publication of MX2017006744A publication Critical patent/MX2017006744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición adyuvante que es adecuada para una administración inyectable así como también transdérmica. La composición adyuvante generalmente comprende un lipófilo, un polímero de ácido acrílico o metacrílico, solución salina, colesterol, una saponina e hidróxido de sodio. También se proporciona una composición de vacuna que generalmente incluye la composición de vacuna de la presente descripción y un antígeno. También se proporciona un método para vacunar animales y humanos usando la composición adyuvante de la presente descripción.
MX2017006744A 2014-11-26 2015-11-27 Composiciones adyuvantes y metodos relacionados. MX2017006744A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084698P 2014-11-26 2014-11-26
US201562137659P 2015-03-24 2015-03-24
PCT/US2015/062836 WO2016086222A1 (en) 2014-11-26 2015-11-27 Adjuvant compositions and related methods

Publications (1)

Publication Number Publication Date
MX2017006744A true MX2017006744A (es) 2017-08-16

Family

ID=56075072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006744A MX2017006744A (es) 2014-11-26 2015-11-27 Composiciones adyuvantes y metodos relacionados.

Country Status (9)

Country Link
EP (1) EP3223846B1 (es)
JP (1) JP6802790B2 (es)
AU (1) AU2015353376B2 (es)
CA (1) CA2968389C (es)
DK (1) DK3223846T3 (es)
ES (1) ES2961965T3 (es)
MX (1) MX2017006744A (es)
PL (1) PL3223846T3 (es)
WO (1) WO2016086222A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
CA2979556C (en) * 2015-03-24 2023-07-18 VaxLiant, LLC Adjuvant compositions and related methods
CA3106341A1 (en) 2018-07-13 2020-01-16 Biomune Company New vaccines against avian reoviruses
CA3147040A1 (en) 2019-07-12 2021-01-21 Biomune Company Method for vaccinating avians against reovirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CN104758929B (zh) * 2008-06-27 2018-05-25 硕腾有限责任公司 新颖的佐剂组合物
CA2866170A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
CA2890110C (en) * 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells

Also Published As

Publication number Publication date
CA2968389C (en) 2023-12-12
EP3223846A1 (en) 2017-10-04
JP6802790B2 (ja) 2020-12-23
WO2016086222A1 (en) 2016-06-02
EP3223846B1 (en) 2023-09-06
AU2015353376B2 (en) 2021-03-25
JP2017537106A (ja) 2017-12-14
DK3223846T3 (da) 2023-11-20
CA2968389A1 (en) 2016-06-02
EP3223846A4 (en) 2018-07-25
BR112017010883A2 (pt) 2017-12-26
ES2961965T3 (es) 2024-03-14
PL3223846T3 (pl) 2024-03-11
AU2015353376A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2017012220A (es) Composiciones adyuvantes y metodos relacionados.
EA201790398A1 (ru) Способы лечения заболевания печени
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
TW201613556A (en) Swine virus vaccines that are liquid stable
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
WO2015168379A3 (en) Combination vaccine devices and methods of killing cancer cells
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
TN2018000188A1 (en) Isoindole compounds
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
IN2015KN00516A (es)
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
ES2503516R1 (es) Complejo inmunogénico para vacunación y método de obtención